vs
Side-by-side financial comparison of PILGRIMS PRIDE CORP (PPC) and Zoetis (ZTS). Click either name above to swap in a different company.
PILGRIMS PRIDE CORP is the larger business by last-quarter revenue ($4.5B vs $2.4B, roughly 1.9× Zoetis). Zoetis runs the higher net margin — 25.3% vs 1.9%, a 23.3% gap on every dollar of revenue. On growth, PILGRIMS PRIDE CORP posted the faster year-over-year revenue change (3.3% vs 3.0%). Zoetis produced more free cash flow last quarter ($732.0M vs $10.0M). Over the past eight quarters, Zoetis's revenue compounded faster (4.4% CAGR vs 1.8%).
Pilgrim's Pride Corporation is an American, multi-national food company, currently one of the largest chicken producers in the United States and Puerto Rico and the second-largest chicken producer in Mexico. It exited bankruptcy in December 2009 and relocated its U.S. headquarters to Greeley, Colorado, in 2011. It is majority-owned by JBS S.A. Pilgrim's Pride purchased Gold'n Plump for $350 million in late November 2016.
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
PPC vs ZTS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $4.5B | $2.4B |
| Net Profit | $88.0M | $603.0M |
| Gross Margin | 9.5% | 70.2% |
| Operating Margin | 4.5% | 31.9% |
| Net Margin | 1.9% | 25.3% |
| Revenue YoY | 3.3% | 3.0% |
| Net Profit YoY | -62.7% | 3.8% |
| EPS (diluted) | $0.37 | $1.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $4.5B | $2.4B | ||
| Q3 25 | $4.8B | $2.4B | ||
| Q2 25 | $4.8B | $2.5B | ||
| Q1 25 | $4.5B | $2.2B | ||
| Q4 24 | $4.4B | $2.3B | ||
| Q3 24 | $4.6B | $2.4B | ||
| Q2 24 | $4.6B | $2.4B | ||
| Q1 24 | $4.4B | $2.2B |
| Q4 25 | $88.0M | $603.0M | ||
| Q3 25 | $342.8M | $721.0M | ||
| Q2 25 | $355.5M | $718.0M | ||
| Q1 25 | $296.0M | $631.0M | ||
| Q4 24 | $235.9M | $581.0M | ||
| Q3 24 | $349.9M | $682.0M | ||
| Q2 24 | $326.3M | $624.0M | ||
| Q1 24 | $174.4M | $599.0M |
| Q4 25 | 9.5% | 70.2% | ||
| Q3 25 | 13.9% | 71.5% | ||
| Q2 25 | 15.0% | 73.6% | ||
| Q1 25 | 12.4% | 72.0% | ||
| Q4 24 | 12.7% | 69.5% | ||
| Q3 24 | 14.9% | 70.6% | ||
| Q2 24 | 15.2% | 71.7% | ||
| Q1 24 | 8.8% | 70.6% |
| Q4 25 | 4.5% | 31.9% | ||
| Q3 25 | 10.4% | 37.0% | ||
| Q2 25 | 10.8% | 36.7% | ||
| Q1 25 | 9.1% | 36.5% | ||
| Q4 24 | 7.0% | 31.6% | ||
| Q3 24 | 11.1% | 36.6% | ||
| Q2 24 | 9.7% | 33.0% | ||
| Q1 24 | 5.7% | 34.1% |
| Q4 25 | 1.9% | 25.3% | ||
| Q3 25 | 7.2% | 30.0% | ||
| Q2 25 | 7.5% | 29.2% | ||
| Q1 25 | 6.6% | 28.4% | ||
| Q4 24 | 5.4% | 25.1% | ||
| Q3 24 | 7.6% | 28.6% | ||
| Q2 24 | 7.2% | 26.4% | ||
| Q1 24 | 4.0% | 27.4% |
| Q4 25 | $0.37 | $1.37 | ||
| Q3 25 | $1.44 | $1.63 | ||
| Q2 25 | $1.49 | $1.61 | ||
| Q1 25 | $1.24 | $1.41 | ||
| Q4 24 | $1.00 | $1.29 | ||
| Q3 24 | $1.47 | $1.50 | ||
| Q2 24 | $1.37 | $1.37 | ||
| Q1 24 | $0.73 | $1.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $640.2M | — |
| Total DebtLower is stronger | $3.1B | — |
| Stockholders' EquityBook value | $3.7B | $3.3B |
| Total Assets | $10.3B | $15.5B |
| Debt / EquityLower = less leverage | 0.84× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $640.2M | — | ||
| Q3 25 | $612.6M | $2.1B | ||
| Q2 25 | $849.0M | $1.4B | ||
| Q1 25 | $2.1B | $1.7B | ||
| Q4 24 | $2.0B | $2.0B | ||
| Q3 24 | $1.9B | $1.7B | ||
| Q2 24 | $1.3B | $1.6B | ||
| Q1 24 | $870.8M | $2.0B |
| Q4 25 | $3.1B | — | ||
| Q3 25 | $3.1B | — | ||
| Q2 25 | $3.1B | — | ||
| Q1 25 | $3.2B | — | ||
| Q4 24 | $3.2B | — | ||
| Q3 24 | $3.2B | — | ||
| Q2 24 | $3.2B | — | ||
| Q1 24 | $3.3B | — |
| Q4 25 | $3.7B | $3.3B | ||
| Q3 25 | $3.5B | $5.4B | ||
| Q2 25 | $3.7B | $5.0B | ||
| Q1 25 | $3.1B | $4.7B | ||
| Q4 24 | $4.2B | $4.8B | ||
| Q3 24 | $4.2B | $5.2B | ||
| Q2 24 | $3.7B | $5.0B | ||
| Q1 24 | $3.5B | $5.1B |
| Q4 25 | $10.3B | $15.5B | ||
| Q3 25 | $10.0B | $15.2B | ||
| Q2 25 | $10.1B | $14.5B | ||
| Q1 25 | $11.0B | $14.1B | ||
| Q4 24 | $10.7B | $14.2B | ||
| Q3 24 | $10.7B | $14.4B | ||
| Q2 24 | $10.1B | $14.2B | ||
| Q1 24 | $9.8B | $14.3B |
| Q4 25 | 0.84× | — | ||
| Q3 25 | 0.87× | — | ||
| Q2 25 | 0.83× | — | ||
| Q1 25 | 1.02× | — | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 0.76× | — | ||
| Q2 24 | 0.85× | — | ||
| Q1 24 | 0.96× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $291.2M | $893.0M |
| Free Cash FlowOCF − Capex | $10.0M | $732.0M |
| FCF MarginFCF / Revenue | 0.2% | 30.7% |
| Capex IntensityCapex / Revenue | 6.2% | 6.7% |
| Cash ConversionOCF / Net Profit | 3.31× | 1.48× |
| TTM Free Cash FlowTrailing 4 quarters | $653.1M | $2.3B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $291.2M | $893.0M | ||
| Q3 25 | $458.3M | $938.0M | ||
| Q2 25 | $495.2M | $486.0M | ||
| Q1 25 | $126.9M | $587.0M | ||
| Q4 24 | $349.3M | $905.0M | ||
| Q3 24 | $651.1M | $951.0M | ||
| Q2 24 | $718.6M | $502.0M | ||
| Q1 24 | $271.0M | $595.0M |
| Q4 25 | $10.0M | $732.0M | ||
| Q3 25 | $275.9M | $805.0M | ||
| Q2 25 | $339.1M | $308.0M | ||
| Q1 25 | $28.1M | $438.0M | ||
| Q4 24 | $176.6M | $689.0M | ||
| Q3 24 | $565.3M | $784.0M | ||
| Q2 24 | $617.7M | $370.0M | ||
| Q1 24 | $171.9M | $455.0M |
| Q4 25 | 0.2% | 30.7% | ||
| Q3 25 | 5.8% | 33.5% | ||
| Q2 25 | 7.1% | 12.5% | ||
| Q1 25 | 0.6% | 19.7% | ||
| Q4 24 | 4.0% | 29.7% | ||
| Q3 24 | 12.3% | 32.8% | ||
| Q2 24 | 13.5% | 15.7% | ||
| Q1 24 | 3.9% | 20.8% |
| Q4 25 | 6.2% | 6.7% | ||
| Q3 25 | 3.8% | 5.5% | ||
| Q2 25 | 3.3% | 7.2% | ||
| Q1 25 | 2.2% | 6.7% | ||
| Q4 24 | 4.0% | 9.3% | ||
| Q3 24 | 1.9% | 7.0% | ||
| Q2 24 | 2.2% | 5.6% | ||
| Q1 24 | 2.3% | 6.4% |
| Q4 25 | 3.31× | 1.48× | ||
| Q3 25 | 1.34× | 1.30× | ||
| Q2 25 | 1.39× | 0.68× | ||
| Q1 25 | 0.43× | 0.93× | ||
| Q4 24 | 1.48× | 1.56× | ||
| Q3 24 | 1.86× | 1.39× | ||
| Q2 24 | 2.20× | 0.80× | ||
| Q1 24 | 1.55× | 0.99× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PPC
| Retail | $1.5B | 33% |
| Europe Reportable Segment | $1.4B | 31% |
| Food Service | $889.2M | 20% |
| Prepared Product | $332.8M | 7% |
| Product Export | $122.7M | 3% |
| Other Sales Channel | $96.0M | 2% |
| Other Product And Service | $79.7M | 2% |
| Related Party | $21.7M | 0% |
| Seara Meats B.V. | $18.9M | 0% |
| Penasul UKLTD | $10.3M | 0% |
| JBSUSA Food Company | $5.4M | 0% |
ZTS
| Other | $1.3B | 56% |
| Livestock | $234.0M | 10% |
| Pain Sedation | $209.0M | 9% |
| Other Pharmaceuticals | $188.0M | 8% |
| Swine | $125.0M | 5% |
| Poultry | $117.0M | 5% |
| Fish | $81.0M | 3% |
| Other Non Pharmaceuticals | $70.0M | 3% |
| Manufactured Product Other | $18.0M | 1% |
| Medicated Feed Additives | $12.0M | 1% |
